Robinson PC. Yazdany J (2020) The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020;166(16):293–4.

Article  Google Scholar 

•• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–66. Using the newly created C19-GRA registry to determine patient factors associated with COVID-19 hospitalization.

Article  CAS  PubMed  Google Scholar 

Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930–42.

Article  CAS  PubMed  Google Scholar 

Kearsley-Fleet L, Chang ML, Lawson-Tovey S, et al. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2022;81:998–1005.

Article  CAS  PubMed  Google Scholar 

D’Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021;33:255–61.

Article  PubMed  PubMed Central  Google Scholar 

Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol (Hoboken, NJ). 2020;72:1241–51.

Article  CAS  Google Scholar 

Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis Rheumatol (Hoboken, NJ). 2020;72:e1–12.

CAS  Google Scholar 

Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheumatol. 2021;73(2):e1–12. https://doi.org/10.1002/art.41596.

Article  CAS  PubMed  Google Scholar 

Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology guidance for the management of pediatric rheumatic disease during the COVID-19 pandemic: version 1. Arthritis Rheumatol (Hoboken, NJ). 2020;72:1809–19.

Article  CAS  Google Scholar 

Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology guidance for the management of pediatric rheumatic disease during the COVID-19 pandemic: version 2. Arthritis Rheumatol (Hoboken, NJ). 2021;73:e46–59.

CAS  Google Scholar 

Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76:1559–65.

Article  CAS  PubMed  Google Scholar 

Park JK, Lee YJ, Shin K, Ha YJ, Lee EBY, Song YW, Choi Y, Winthrop KL, Lee EBY. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77:898–904.

CAS  PubMed  Google Scholar 

Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80:1330–8.

Article  CAS  PubMed  Google Scholar 

• Furer V, Eviatar T, Freund T, et al. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study Ann Rheum Dis. 2022;81:1594-602.

•• Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis Autoimmun Rev. 2022;21:102927. https://doi.org/10.1016/j.autrev.2021.102927. Meta-analysis of 25 studies investigating seroconversion rates following SARS-CoV-2 vaccination in patients with immune mediated inflammatory diseases. They found that anti-CD20 therapy negatively impacted seroconversion.

Bin LARY, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632.

Google Scholar 

Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4:e338–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity following the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic diseases: a prospective multicentre study. Vaccines. 2023;11:819.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385:1244–6.

Article  PubMed  Google Scholar 

Ku JH, Sy LS, Qian L, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. Vaccine. 2023;41:3636–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021;80:1355–6.

Article  CAS  PubMed  Google Scholar 

Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases Arthritis Care Res. 2023;75:449-64.

Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1. Arthritis Rheumatol (Hoboken, NJ). 2021;73:1093–107.

Article  CAS  Google Scholar 

Curtis JR, Johnson SR, Anthony DD, et al (2021) American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2. Arthritis Rheumatol (Hoboken, NJ). https://doi.org/10.1002/ART.41877.

Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3. Arthritis Rheumatol (Hoboken, NJ). 2021;73:e60–75.

CAS  Google Scholar 

Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol (Hoboken, NJ). 2022;74:21-e36.

Google Scholar 

• Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5 Arthritis Rheumatol (Hoboken, NJ). 2023;75:E1-E16.

Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–602.

Article  PubMed  PubMed Central  Google Scholar 

Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm Regen. 2020;40:1–6.

Article  Google Scholar 

Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-4.

Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD014963.

Article  PubMed  PubMed Central  Google Scholar 

• Marko M, Pawliczak R. Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials Sci Rep. 2023;13:1-1.

Leligdowicz A, Harhay MO, Calfee CS. Immune modulation in sepsis, ARDS, and Covid-19 — the road traveled and the road ahead. NEJM Evid. 2022. https://doi.org/10.1056/EVIDra2200118.

Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10: 428603.

Article  Google Scholar 

Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol. 2003;1:17–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW. Infliximab concentrations in participants with moderate to severe COVID-19 J Clin Pharmacol. 2023;1:2.

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56: 105949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–25.

Article  CAS  PubMed  Google Scholar 

Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA - J Am Med Assoc. 2020;324:2165–76.

Article  CAS  Google Scholar 

Mendel A, Bernatsky S, Askanase A, et al. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Ann Rheum Dis. 2021;80:272–4.

Article  Google Scholar 

State action on hydroxychloroquine and chloroquine access | Lupus Foundation of America. https://www.lupus.org/advocate/state-action-on-hydroxychloroquine-and-chloroquine-access. Accessed 1 Feb 2024.

Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12:2349.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–40.

Pradelle A, Mainbourg S, Provencher S, Massy E, Grenet G, Lega J. Biomedicine & pharmacotherapy deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate. Biomed Pharmacother. 2024;171:116055.

Udupa A, Leverenz D, Balevic SJ, Sadun RE, Tarrant TK, Rogers JL. Hydroxychloroquine and COVID-19: a rheumatologist’s take on the lessons learned. Curr Allergy Asthma Rep. 2021;21:5.

Balevic SJ, Hornik CP, Green TP, et al. Hydroxychloroquine in patients with rheumatic disease complicated by COVID-19: clarifying target exposures and the need for clinical trials. J Rheumatol. 2020;47:1424–30.

Article  CAS  Google Scholar 

•• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;(80- ). https://doi.org/10.1126/science.abd4585. First discovery of neutralizing human anti-interferon antibodies.

Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021. https://doi.org/10.1126/sciimmunol.abl4340.

Article  PubMed  PubMed Central  Google Scholar 

Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283–8.

Article  CAS